InvestorsHub Logo
Followers 826
Posts 119062
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 817

Friday, 01/27/2023 10:25:43 AM

Friday, January 27, 2023 10:25:43 AM

Post# of 864
FDA approves Keytruda for adjuvant NSCLC following adjuvant treatment with platinum chemo:

Keytruda’s HR for DFS (compared to placebo) was 0.73 [95% CI: 0.60-0.89]. This is slightly better than the HR=0.76 that MRK reported when the KEYNOTE-091 trial reported in Mar 2022 (#msg-168241140); I do not know the reason for the discrepancy.

Curiously, in an exploratory analysis of patients (n=167) who did not receive adjuvant chemo, Keytruda’s HR for DFS (relative to placebo) was 1.25 (i.e. the Keytruda arm did worse than placebo), but the 95% confidence interval was wide [0.76-2.05].

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News